On July 9th, President Obama signed into law the FDA Safety and Innovation Act, legislation with many provisions to support research and treatments for rare disorders.
Among the new law’s provisions of interest to the rare disease community:
• Provisions to encourage accelerated patient access to new medical treatments
• The development of Humanitarian Use Devices (medical devices for small patient populations)
• Accelerated development of “breakthrough therapies” that show early promise
• Enhanced FDA consultation with rare disease experts
• A rare pediatric disease priority review voucher incentive program to encourage development of treatments for rare pediatric disorders
• Resolution of conflict of interest issues that have kept some rare disease experts out of the decision making process
• Research into how to make drug labels more accessible to the blind and visually impaired
Comments